HR Execs on the Move

Pharmaceutics International

www.pharm-int.com

 
Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii`s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer contract analytical development and support formulation and manufacturing of oral solid dosage forms. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
John Phillips
 Vice President of Sales Profile
James Drob
 Head of Aseptic Manufacturing, Supply Chain and Validation Profile
Joseph Kiely
 Chief Financial Officer Profile
Alexander Borodin
 Senior Director of Supply Chain Profile
George Sanders
 Vice President of Human Resources Profile

Similar Companies

West Hill Gastroenterology

West Hill Gastroenterology is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triangle Compounding Pharmacy

Triangle Compounding Pharmacy is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Schmidt and Sons Pharmacy Inc

Schmidt & Sons Pharmacy Inc is a Tecumseh, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenocor

Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.